Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · IEX Real-Time Price · USD
4.260
+0.230 (5.71%)
At close: Jul 19, 2024, 4:00 PM
4.290
+0.030 (0.70%)
Pre-market: Jul 22, 2024, 7:21 AM EDT
Jaguar Health Revenue
Jaguar Health had revenue of $10.14M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $2.35M with 19.22% year-over-year growth. In the year 2023, Jaguar Health had annual revenue of $9.76M.
Revenue (ttm)
$10.14M
Revenue Growth
-10.29%
P/S Ratio
2.05
Revenue / Employee
$206,939
Employees
49
Market Cap
20.83M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
Dec 31, 2018 | 4.42M | 54.96K | 1.26% |
Dec 31, 2017 | 4.36M | 4.22M | 2,981.61% |
Dec 31, 2016 | 141.52K | -116.86K | -45.23% |
Dec 31, 2015 | 258.38K | - | - |
Dec 31, 2014 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cosmos Health | 49.59M |
Cumberland Pharmaceuticals | 38.83M |
TRxADE HEALTH | 6.66M |
Singular Genomics Systems | 2.49M |
TherapeuticsMD | 1.20M |
Oncternal Therapeutics | 1.15M |
AIM ImmunoTech | 193.00K |
JAGX News
- 3 days ago - Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning - Accesswire
- 25 days ago - Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement - Accesswire
- 4 weeks ago - Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders - Accesswire
- 5 weeks ago - Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 - Accesswire
- 6 weeks ago - Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 2 months ago - Jaguar Health, Inc. Announces Reverse Stock Split - Accesswire
- 2 months ago - Jaguar Health Reports First Quarter 2024 Financial Results - Accesswire
- 2 months ago - REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates - Accesswire